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Abstract 
 
Police services in a number of Australian states and overseas jurisdictions have begun to 
implement or consider random road-side drug testing of drivers. This paper outlines 
research conducted to provide an estimate of the prevalence of drug driving in a sample of 
Queensland drivers in a metropolitan and regional area e.g. Brisbane and Townsville. Oral 
fluid samples were collected from 2381 motorists who volunteered to participate in the 
study after proceeding from a Random Breath Testing site (Brisbane = 1587 & Townsville = 
794). Illicit substances were screened using the Cozart RapiScan oral fluid drug test device 
and included cannabis (delta 9 tetrahydrocannibinol [THC]), amphetamines, ecstasy, and 
cocaine. Drivers also completed a self-report questionnaire regarding their drug driving 
behaviour. Overall, 3.8% of the sample (n = 92) screened positive for at least one illicit 
substance, although multiple drugs were identified in a sample of 19 participants. The most 
common drugs detected in oral fluid were ecstasy (n = 51), cannabis (n = 40), followed by 
amphetamines (n = 20). A key finding was that cannabis was confirmed as the most 
common self-reported drug combined with driving and that individuals who tested positive 
to any drug through oral fluid analysis were also more likely to report the highest frequency 
of drug driving. Furthermore, a comparison between the two areas revealed drug driving 
detections rates were comparatively similar. This research provides evidence that drug 
driving is relatively prevalent on Queensland roads and may in fact be more common than 
drink driving.     
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Introduction 
 
At present, an increasingly amount of research effort has been focused on determining 
the prevalence and impact of drug driving on road safety. As a result, a substantial body of 
research is accruing that has focused on identifying the presence of illicit drugs in body 
fluids of those who have been involved in a crash (Del Rio, Gomez, Sancho, & Alvarez, 
2002; Drummer, Gerostamoulos, Batziris, Chu, Caplehorn, Robertson, et al., 2003). For 
example, research has revealed that the presence of illicit drugs was identified in anywhere 
between 8.8% and 39.6% of such drivers (Del Rio, et al. 2002; Drummer, et al., 2003; 
Gjerde, Beylich, & Morland, 1993; Mura, Chatelain, Dumestre, Gaulier, Ghysel, Lacroix, et 
al., 2006; Seymour & Oliver, 1999; Swann, Boorman, & Papafotiou, 2004).  Additionally, 
illicit drugs is also prevalent amongst non fatally injured drivers, with illicit substances 
including the predominate cannabis, found in anywhere between 2.7 and 41.3% of such 
drivers (Athanaselis, Dona, Papadodima, Papoutsis, Maravelias, & Koutselinis, 1999; 
Longo, Hunter, Lokan, White, & White, 200l; Soderstrom, Dischinger, Kerns, & Trifillis, 
1995; Stoduto, Vingilis, Kapur, Sheu, McLellan, & Liban, 1993; Waller, Blow, Maio, 
Singer, Hill, & Schaefer, 1997). Not surprisingly, the illicit drug identified most often in the 
body fluids of drivers involved in motor vehicle crashes is cannabis. From an Australian 
perspective, Drummer, et al. (2003), investigated drivers in fatal crashes from three 
Australian states (Victoria, New South Wales and Western Australia) and found a robust 
relationship between drug driving and culpability, with the accident risk estimated as high as 
a driver with a blood alcohol content of 0.1 to 0.15 percent. To address this growing road 
safety issue, the introduction of new detection methods are currently being implemented in a 
number of jurisdictions.  More specifically, in Queensland, the commencement of Random 
Roadside Drug Testing has commenced and the effectiveness of this countermeasure is yet 
to be established.     
Beyond those drug drivers involved in crashes, little research is available 
investigating the prevalence of the behaviour within the general community. The current 
community perspective of drug driving is that it is relatively rare (Kelly, Darke & Ross, 
2004). In challenging this notion, the 2007 National Drug Strategy Household Survey 
(NDSHS) provides some support that drug driving may be quite prevalent in Australia. The 
survey enquired as to the activities undertaken while under the influence of illicit drugs, 
with 2.9% of Australians indicating driving a motor vehicle (AIHW, 2007). Additionally, 
one of the more useful reports exploring drug driving in the Australian community was 
published by the Australian Drug Foundation (ADF) (Mallick, Johnston, Goran, & 
Kennedy, 2007). The aim of the project was to capture a community-wide impression of 
drug driving behaviour. The most prominent finding was the self-reported prevalence of 
drug driving in the previous 12 months, with 12.3% of the sample indicating driving within 
three hours of using cannabis, whilst a proportion of drivers (6.9%) reported driving within 
three hours of using methamphatamines.  
However, a growing body of research has revealed that the self reported prevalence of 
drug driving varies distinctly between 2% and 90% of respondents, although the majority of 
the research suggests between 3% and 10% (Kelly, Darke, & Ross, 2004). Regardless of 
this research, amongst some subcultures, researchers have suggested the prevalence of drug 
driving in the community is significantly higher (Akram, 1997; Terry & Wright, 2005). For 
instance, Akram (1997) found that amphetamine use among some samples was 62%, whilst 
more surprisingly, drug driving amongst a sample of cannabis users revealed a prevalence 
rate of approximately 82% (Terry & Wright, 2005). Overall, research has suggested that the 
common drug combined with driving is cannabis (Davey, Leal, & Freeman, 2007; 
Drummer, et al. 2003; Terry & Wright, 2005), which may in fact be related with the general 
perceptions that cannabis does not have a harmful effect on driving ability. Nonetheless, 
amphetamine use and driving are also regularly combined among some sub-groups of 
motorists (Albery, Strang, Gossop, & Griffiths, 2000; Kelly, Darke, & Ross, 2004; Davey, 
Leal, & Freeman, 2007).  
Additionally, Australian research that has focused on university students or younger 
drivers have found similar results, with between 8.2% and 15% of motorists reporting 
driving after consuming some form of illicit drug. (Armstrong, Wills, & Watson, 2005; 
Davey, Davey, & Obst, 2005a).  A similar Australian study that investigated the use of 
illicit substances in road crashes, indicated that 16.4% of injured motorists tested positive to 
cannabis and a further 6.9% tested positive to the presence of amphetamines (Caldicott, 
Pfeiffer, Edwards, Pearce, & Davey, 2007). In spite of this, the difficulty with capturing an 
accurate representation of drug driving in the general community rests on the fact that 
drivers arbitrated at fault in a crash are therefore more likely to be tested for the presence of 
drugs and consequently are shown in research and statistics of this kind (Drummer, 
Gerostamoulos, Chu, Swann, Boorman, & Cairns, 2007). As a result, the challenge of 
capturing a true representation of the prevalence of drug driving remains difficult.  
The development and use of roadside drug testing of oral fluid, has significantly 
improved the chances of correctly ascertaining a better understanding of the extent of drug 
driving in the community, since testing is non- invasive and straightforward (Dolan, Rouen 
& Kimber, 2004; Speedy, Baldwin, Hand, & Jehanli, 2004). In contrast, research regarding 
sampling of body fluids has originally focused on sampling drivers involved in motor 
vehicle crashes or those drivers suspected of driving under the influence of illicit 
substances. Therefore the development of the oral fluid testing has allowed researchers to 
provide an estimate of the extent of drug driving on public roads, together with those 
involved in crashes. One such study in this area randomly sampled a group of motorists in 
Britain and found 4.7% of drivers were confirmed positive to the presence of drugs 
(Buttress, Tunbridge, Oliver, Torrance, & Wylie, 2004). However, in comparison, a much 
higher result was found in a study conducted in Germany, which suggested that 16.8% of 
randomly selected motorists confirmed positive to at least one illicit drug (Wylie, Torrance, 
Seymour, Buttress, & Oliver, 2005).  
In the Australian context, one of the few studies in this specific area was conducted by 
the Victorian police who randomly tested motorists for the presence of drugs and found a 
drug driving prevalence rate of approximately 2.4% or one driver in 40 for substances 
including cannabis and amphetamines (Drummer, et al., 2007). Additionally, Davey, Leal 
and Freeman (2007), investigated the prevalence of drug driving amongst a sample of 
Queensland motorists recruited from a Random Breath Testing site and found that 3.5% of 
motorists tested positive to at least one illicit substance, which was significantly greater than 
the overall drink driving rates during the same period. Furthermore, another study adding to 
the gravity of the drug driving problem in Australia is a study by Poyser, Makkai, Norman 
and Mills (2002) who examined drug driving in a sample of traffic detainees from three 
Australian states. The authors collected samples over a three year period from 1999-2001 
and included anyone who was being charged for a driving related offence. The major 
finding of the study was that 71% of the sample tested positive to one drug and over one 
third of the sample (37%) tested positive to more than one drug. These preliminary findings 
indicate that drug driving presents as a serious threat to road safety and additionally, 
warrants the need further research to determine the prevalence of non-crash drug driving 
rates in Australia, especially for drugs such as cannabis, amphetamines, ecstasy and 
cocaine. 
As a result, the major objectives of the present study were to: 
• Measure the prevalence of drug driving amongst a sample of Queensland drivers in 
a metropolitan area (Brisbane) and a regional area (Townsville);  
• Investigate the self-reported frequency of general motorists’ engaging in drug 
driving behaviour; and 
• Compare the prevalence of drug driving behaviours in a metropolitan area 
(Brisbane) against a regional area (Townsville). 
 
 
Method 
 
Participants, Materials and Procedure 
Drivers stopped at Random Breath Testing (RBT) sites across 2 locations in Queensland 
(e.g., Brisbane & Townsville), were approached and asked by operational police to 
participate in the drug driving research, which was positioned on average 50 metres further 
down the road. Participation in the study was voluntary and withdrawal was permitted 
anytime without query. Participants were required to complete a self-report questionnaire 
regarding recent illicit drug use and drug driving in the previous 12 months, and provide a 
sample of oral fluid that could later be screened for the presence of drugs. Overall, the 
process took approximately 10-20 minutes to complete and drivers received a one-off 
payment of $20 cash to repay them for their time. Data was collected over a two month 
period, on ten separate occasions, usually between the hours of 5pm and 1am1.   
A 12 item self-report questionnaire was designed to assess a variety of demographic data 
(e.g., gender, age, years driving) as well as self-reported drug use in addition to the 
frequency of drug driving behaviour. Participants responded to questions that examined the 
most recent use of marijuana / cannabis (within four hours, within the last 24 hours, within 
the last week, within the last month, within the last year, more than a year ago, have never 
used). This question was repeated for meth / amphetamines (such as speed, oil, base, and 
crystal), ecstasy, heroin and cocaine. Additionally, participants were also required to indicate 
how often in the previous 12 months they had operated a motor vehicle (including a 
motorcycle) within four hours of using marijuana / cannabis (every day, more than once a 
week, about once a week, 11 – 20 times, 3 – 10 times, once or twice, never). This question 
was also repeated for meth / amphetamines (such as speed, oil, base, and crystal), ecstasy, 
heroin and cocaine.  
In addition, oral fluid samples were collected, stored and screened off-site at a later date 
using the Cozart® RapiScan oral fluid drug testing device. Participants provided a sample of 
oral fluid that was collected from inside their mouth via a pad held either under their tongue 
or beside the inside of their cheek. The five-panel cannabis and single-panel 
methamphetamine / MDMA test cartridges were used (i.e. each sample was screened twice). 
Each Cozart® RapiScan kit consisted of a collector, transport tube containing buffer 
solution, separator filter tube, pipette and test cartridge. The five-panel cannabis cartridge 
detected the presence of benzodiazepines, amphetamines, cannabis (THC), and cocaine, 
while the single-panel methamphetamine / MDMA cartridge detected the presence of 
methamphetamine and MDMA (ecstasy). There was no subjectivity in the interpretation of 
results as the Cozart® RapiScan testing instrument displayed and printed results. 
 
Results 
 
Demographics 
A total of 2381 motorists from the Brisbane and Townsville area volunteered to 
participate in the study. Due to resourcing constraints and the referral process from the 
Police RBT site, it was not possible to obtain an accurate measurement of the response rate 
over the entire data collection period2. However, on one occasion in the Townsville region 
the response rate was assessed across two sites during a shift where an additional researcher 
counted the number of drivers approached to participate and noted their response. Drivers of 
63 cars from a total of 85 participated in the project, resulting in a response rate of 74.12 
percent. A similar approach was taken on one occasion for the Brisbane area which 
confirmed a 71.4% response rate. In addition, over the entire study, six potential participants 
approached the research site, but declined to participate after being informed about the 
research procedure.    
The sample was predominantly male, featuring 1487 (62.5%) males as compared to 
873 (36.7%) females, with 21 participants electing not to provide their gender. Overall, the 
mean age of the sample was 28.88 years (SD = 11.64), with participant ages ranging 
                                                 
1 Workplace health and safety requirements resulted in the current roadside project only being implemented 
with the presence of the Queensland Police Service.  RBT operations were deemed to be the most compatible 
roadside activity and thus drug testing procedures corresponded within traditional RBT operational hours e.g., 
5pm – 1am.   
2 The procedure usually consisted of RBT operational police officers informing motorists (who had given a 
breath sample) that they had the opportunity to participate in an anonymous research drug driving project 
being conducted approximately 100 metres down the road.   
between 16 and 75. To this end, average age was identified as a noteworthy difference 
between the participant groups, with the Brisbane group (M = 30.05 years, SD = 12.01) 
found to be significantly older than the Townsville group (M = 26.32, SD = 10.40), t (1581) 
= 7.44, p< .001). On average, participants had been driving for 11.04 years (SD = 10.96) 
with the majority of the sample reporting driving daily (n = 1940, 82.3%) or three to five 
times per week (n = 358, 15.2%).  
Prevalence of Positive Drug Screening Tests 
Screening analysis revealed that oral fluid samples from 92 drivers (3.86% of the total 
sample) contained at least one illicit substance. Chi-square analysis between the two regions 
revealed a similar proportion of respondents screened positive to at least one drug. 
Additionally, a comparison was undertaken between the drink driving and drug driving 
detection rates for the Townsville area which revealed that drug driving detection rates were 
substantially more prevalent (3.86%) than drink driving (0.8%3). Table 1 outlines the results 
by drug group detected in the two regions. As depicted in Table 1, the most common drug 
detected was ecstasy (MDMA) (n = 51), followed by cannabis (THC) (n = 40), 
amphetamines (n = 20) and cocaine (n = 4 cases). Differences between the two regions were 
identified on positive drug screening tests of cannabis, as participants in Townsville were 
significantly more likely to test positive to cannabis than participants in Brisbane X2 (1, N = 
2381, = 5.114, p =.024). The positive screening of amphetamines, ecstasy and cocaine 
revealed no significant differences between the two regions. In regards to poly drug use, 19 
samples (0.79%) were screened as positive for 2 drugs, while 2 samples tested positive for 3 
drugs.  
Compared with the total participant pool, the 92 drivers who provided samples that 
were confirmed positive for at least one illicit substance were more likely to be male (n = 73, 
79.3%), marginally younger than non-positive participants (m = 25.2 years, SD = 7.96) and 
had less driving experience (m = 7.9 years, SD = 8.0). Furthermore, males were 4 times more 
likely engage in poly drug use (n = 16, 84%). Overall, a similar proportion of participants in 
both regions tested positive to at least one drug. 
 
Table 1. Number and Proportion of Positive Screening Tests by Drug Group  
  Total  N = 2381 
 Brisbane 
 N = 1587 
 Townsville 
 N = 794 
Ecstasy (MDMA)  51 (2.14%)  35 (2.21%)  16 (2.02%) 
Cannabis (THC)  40 (1.68%)  20 (1.26%)  20 (2.52%) 
Amphetamines  20 (0.84%)  17 (1.07%)  3 (0.38%) 
 Cocaine  4 (0.17%)  2 (0.13%)  2 (0.25%) 
Total Illicit Substances4  115 (4.83%)  74 (4.66%)  41 (5.16%) 
 
                                                 
3 Relatively few individuals charged with drink driving participated in the drug driving research, and thus the drug 
and drinking drivers consisted of separate samples.  
4 19 respondents screened positive to more than one drug 
 Self-reported Prevalence of Drug Driving 
An investigation was also undertaken to examine participants’ self-reported drug use 
and drug driving behaviours. Firstly, regarding drug use, the most commonly consumed 
drug was cannabis, with 23% reporting the use of the substance within the last year, and 
8.2% of this group reporting usage in the last week. In contrast, only 8% reported 
amphetamine use in the last year and 7.1% MDMA/ecstasy use in the last year. A point to 
note is that in Queensland many illicit drug users refer to methylamphetamine as 
amphetamine. Additionally 2.4% reported using cocaine and 0.3% of the sample reported 
using heroin during the last year. Chi-square analysis revealed males were more likely to 
report regular cannabis use than females X2 (6, N = 2357, = 35.94, p <.001), while small cell 
sizes precluded analysis of the other substances. Lastly, differences were identified between 
the regions on self-reported frequency of drug use, as participants in Townsville reported 
higher frequencies of cannabis use, X2 (12, N = 2378, = 15.91, p =.014) than participants in 
Brisbane. However, small cell sizes again excluded further chi-square analysis of the drug 
types and regions. 
Conversely, investigation of the self reported prevalence of drug driving revealed the 
most common substance combined with driving was reported to be cannabis (see Table 2). 
More specifically, 4.4% of the sample reported using cannabis before driving at least once a 
week, whilst approximately 1.0% reported the use of amphetamines, and less than 1.0% 
reported cocaine or heroin use while driving in a week. Similar to the self reported use of 
cannabis, Townsville participants were significantly more likely to report driving under the 
influence of cannabis than Brisbane participants X2 (6, N = 2328, = 16.06, p = .013), whilst 
small cell sizes precluded analysis of the remaining drug types. Lastly, examination of the 
self-reported drug use for the 92 participants who screened positive to the presence of drugs 
revealed that drug driving was most common among these individuals. More specifically, 
42 (45.6%) reported driving within four hours of using at least one of the drugs outlined on 
the questionnaire. This proportion is more than three times the proportion of the total 
sample of 2381 drivers that reported drug driving (358 drivers, 15%). Furthermore, 45 
(48.9%) of the drivers who provided samples that were confirmed positive for at least one 
illicit substance reported drug driving frequently (that is, once a week or more). This is 
more than 7 times the proportion of the total sample that reported frequently drug driving 
(146 drivers, 6.1%).  
 
Table 2. Drug Driving Behaviour 
Drug Type  Cannabis Amphetamines Ecstasy  Cocaine 
  n  %  n  %  n  %  n  % 
         
Brisbane 
 Every day 
 More than once week 
 About once a week 
 11 - 20 times 
 3 - 10 times 
 Once or twice 
 Never 
 
 26 
 20 
 19 
 14 
 18 
 76 
 1399 
 
(1.6) 
(1.3) 
(1.2) 
(0.9) 
(1.1) 
(4.8) 
(88.2) 
 
 
 3 
 3 
 12 
 12 
 12 
 28 
1509 
 
(0.2) 
(0.2) 
(0.8) 
(0.8) 
(0.8) 
(1.8) 
(95.1) 
 
 1 
 6 
 4 
 7 
    20 
    58 
 1481 
 
(0.1) 
(0.4) 
(0.3) 
(0.4) 
(1.3) 
(3.7) 
(93.3) 
 
 0 
 0 
 0 
 6 
 5 
 22 
1545 
 
(0.0) 
(0.0) 
(0.0) 
(0.4) 
(0.3) 
(1.4) 
(97.4) 
Townsville 
 Every day 
 More than once week 
 About once a week 
 11 - 20 times 
 3 - 10 times 
 Once or twice 
 Never 
 
 
 14 
 13 
 10 
 9 
 15 
 63 
 632 
 
(1.8) 
(1.6) 
(1.3) 
(1.1) 
(1.9) 
(8.3) 
(84.0) 
 
 1 
 2 
 3 
 8 
 5 
 17 
 722 
 
(0.1) 
(0.3) 
(0.4) 
(1.0) 
(0.6) 
(2.1) 
(95.5) 
 
 - 
 - 
 - 
 - 
 - 
 - 
 - 
 
 - 
 - 
 - 
 - 
 - 
 - 
 - 
 
 1 
 2 
 0 
 0 
 0 
 0 
 755 
 
(0.1)
(0.3)
(0.0)
(0.0)
(0.0)
(0.0)
(99.6)
Note: The questionnaire for reporting drug driving behaviour was modified to include ecstasy after testing had been 
completed in Townsville. 
Discussion 
The main objective of this study was to conduct an exploratory study to examine the 
extent of drug driving in both a sample of metropolitan and regional drivers. In particular, 
the study focused on determining the self-reported prevalence of drug driving within the 
samples and the major drug types that are frequently combined with driving. 
Prevalence of Positive Drug Tests 
The first primary finding of the study was that 3.8% (n = 92) of the sample provided a 
positive illicit drug reading. This finding is consistent with previous preliminary research 
that has focused on randomly drug testing motorists through oral fluid analysis (Buttress, et 
al., 2004; Davey, Leal, & Freeman, 2007; Drummer, et al., 2007). Secondly, the results 
revealed that the detection rate for drug drivers, in the present study, appears considerably 
higher than the detection rates for drink drivers in Queensland (Davey, et al., 2007; 
Watson, Hart, Freeman, Tay, Davey, Madden, et al., 2005). Nonetheless, the current 
findings are still merely preliminary and the sample only focuses on two specific areas in 
Queensland e.g. Brisbane and Townsville. Therefore results may differ depending on the 
location that the sample is taken from. Even so, the findings of the study indicate that a 
substantial proportion of drivers may be at risk of drug driving, rather than drink driving, in 
the early hours of the morning. Additionally, the characteristics of drivers most likely to 
test positive to illicit drugs in the current context were more likely to be males and under 25 
years of age. This finding is consistent with common drug research that has reliably found 
that males are more likely to consume illicit drugs and drive than females (Begg & 
Langley, 2004; Neale, 2004), in particularly engage in poly drug use (Milani, Parrott, 
Turner, & Fox, 2004). 
In regards to the most common illicit substance combined with driving in the current 
study, cannabis was the most prevalent. Similarly, the prevalence of positive drug tests in 
both the regional versus the metropolitan area also revealed that cannabis was more 
commonly combined with driving in Townsville, whilst ecstasy and amphetamines were 
frequently combined with driving in Brisbane. These particular findings are somewhat 
contrasting to recent research conducted in Queensland that indicated cannabis was the 
most prevalent combined drug with driving (Davey, Leal, & Freeman, 2007). 
Consequently, it appears that the prevalence of particular drugs may yet be proven to be 
dependent on specific locations, although it is noted the findings need to be replicated with 
larger sample sizes.   
Self-reported Prevalence of Drug Driving 
Examination of the self-reported data revealed that again cannabis was the most 
frequently consumed illicit substance, which is consistent with previous research.  In regards 
to the most prevalent drug combined with driving in the different regions, cannabis was the 
most prevent in the regional area, whilst ecstasy was the most common drug in the 
metropolitan area. Therefore, these findings suggest that the prevalence of drug use and 
consequently drug driving may be dependent on the region that the sample is derived from. 
These findings are partially supported by previous research that has suggested cannabis to be 
the most prevalent drug associated with driving (Davey, Leal, & Freeman, 2007; Drummer 
et al., 2003; Seymour & Oliver, 1999; Swann, Boorman, & Papafotiou, 2004).  Importantly, 
those participants who tested positive to the presence of an illicit substance also reported the 
highest frequency of drug driving. Finally, there were few differences identified between the 
regions on key measures such as the number of positive samples. The results indicate that 
drug driving may prove to be a state-wide problem, and additionally, that drug testing may 
have the capacity to detect a considerable proportion of motorists who consume illicit 
substances and drive.    
Limitations  
A number of methodological limitations related with the study should be taken into 
consideration when interpreting the findings. Firstly, the generality of the results may be 
limited as the sample was taken from two areas of Queensland (metropolitan and a regional 
area). Therefore it is possible that drug use and consequently drug driving may possibly 
differ by area due to differences in supply, cost, demand and potency of drugs. 
Additionally, the sample was skewed towards the younger age (M = 28 years), even though 
a wide age range was recorded. Due to the voluntary nature of the study, it was difficult to 
sample a group of drivers that were representative of all Queensland drivers. More 
specifically, the sample of this study may prove to be representative of drivers at night on 
weekends, which is nonetheless a peak drug driving period. Therefore it is possible that the 
frequency of drug driving may increase or decrease into the early hours of the morning as 
well as during the day.  Additionally, the possibility of self-report and volunteer bias 
remains, and although the Queensland Police Service were not directly involved in the 
research project, it is likely that operational officer’s presence at the research site 
discouraged some individuals from participating (especially those under the influence of 
drugs). Questions about the accurateness of saliva testing for illicit drugs in the current 
study also remain, as environmental contamination may negatively influence the accuracy 
of oral testing (for example participants’ presence in a room where cannabis is being 
smoked) (Davey, Leal, & Freeman, 2007). Lastly, in line with previous Queensland 
research, an additional limitation of this study was the delay between sample collection and 
screening, which may have possibly affected the reliability and consistency of the saliva 
samples. However, it was beyond the scope of the current study to screen and test the saliva 
samples at the roadside due to resourcing constraints. Thus it would be ideal to replicate 
and/or expand the current study with a larger sample of drivers across Queensland. Such 
information would further aid in the development and implementation of effective 
countermeasures aimed at reducing the prevalence of drug driving on public roads. 
Nevertheless, the present study provides some confirmation that drug driving may be 
relatively prevalent in both regional and metropolitan areas in Queensland, and since 
research has associated illicit drugs with crash involvement, drug driving presents as a 
serious threat to road safety. Furthermore, as previous research has indicated that 
perceptions of apprehension certainty are a fundamental factor in deterring both drink 
drivers (Piquero & Pogarsky, 2002) and drug drivers (Davey, Davies, French, Williams, & 
Lang, 2005b) from engaging in offending behaviours, random roadside drug testing 
techniques therefore have the ability to become a practical method to increasing 
perceptions of apprehension certainty and consequently reducing the prevalence of drug 
driving. Thus, it would be beneficial to investigate motorists’ current perceptions regarding 
the probability of being detected for drug driving, and their corresponding beliefs about the 
effectiveness and impact of saliva testing on offending rates. This information would 
greatly assist in the implementation of random road side drug testing methods currently 
being conducted in Queensland. Additionally, researchers have revealed that the Australian 
community is presently not adequately aware of the risks related with drug driving 
(Mallick, et al., 2007) and that additional research is necessary to ascertain the most 
effective methods to increasing drivers’ perceptions regarding the harmful impact of illicit 
drugs on driver functioning. In conclusion, further exploration into drug use and 
consequently drug driving can only aid with the development and implementation of 
effective countermeasures directed at decreasing the prevalence of drug driving in the wider 
community.  
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